Skip to main content
SpringerLink
Log in

Comparison of Immunohistochemical Labelling of Melanocyte differentiation Antibodies Melan-A, Tyrosinase and HMB 45 with NKIC3 and S100 Protein in the Evaluation of Benign Naevi and Malignant Melanoma

  • Published:
The Histochemical Journal Aims and scope Submit manuscript

Abstract

A panel of three melanocyte differentiation antibodies has been compared with anti-S100 protein and NKIC3 in an assessment of benign and malignant melanocytic lesions.

Anti-polyclonal S100 protein labelled all cases of primary cutaneous malignant melanoma, metastatic melanoma, desmoplastic melanoma and myxoid melanomas. In addition all benign and dysplastic naevi were positive. Conversely, HMB 45 was the least sensitive marker, labelling 24/31 primary cutaneous melanomas, 14/24 metastatic melanomas and only 1/6 desmoplastic melanomas. In the case of naevi, only junctional forms labelled consistently. Results for anti-melan-A and anti-tyrosinase were similar, although anti-tyrosinase proved slightly more sensitive in cases of malignant melanoma. NKIC3 revealed similar results to anti-tyrosinase, but had the disadvantage of reduced selectivity.

It is concluded that anti-tyrosinase and anti-melan-A are useful additions to the panel of melanocytic monoclonal antibodies. In addition, both antibodies appear to have greater sensitivity for malignant melanoma than the conventionally used HMB 45 and could be considered as supportive markers to polyclonal anti-S100 protein in the diagnosis of malignant melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References cited

  • Achilles E, Schroder S (1994) Positive cytokeratin results in malignant melanoma. Pitfalls in differential immunohistological diagnosis of occult neoplasms. Pathologe 15: 235-241.

    Google Scholar 

  • Anstey A, Cerio R, Ramnarain N, Orchard G, Smith N, Wilson Jones E (1994) Desmoplastic malignant melanoma. An immunocytochemical study of 25 cases. Am J Dermatopathol 16: 14-22.

    Google Scholar 

  • Blessing K, Sanders DS, Grant JJH (1998) Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB 45 in malignant melanoma and melanoma variants. Histopathology 32: 139-146.

    Google Scholar 

  • Bonetti F, Pea M, Martignoni G, Mombello A, Colombari R, Zamboni G, Scarpa A, Piubello Q, Bacchi C, Gowen A (1991) False positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimelanoma monoclonal antibody HMB 45. Am J Clin Pathol 95: 454-459.

    Google Scholar 

  • Gown AM, Vogel AM, Hook D, McNutt MA (1986) Monoclonal antibodies specific for melanocytic tumours distinguish sub-populations of melanocytes. Am J Pathol 123: 195-203.

    Google Scholar 

  • Hostis HL, Deminiere C, Ferreiere JM, Loindre JM (1999) Renal angiomyolipoma. A clinicopathologic, immunohistochemical and follow-up study of 46 cases. Am J Surg Pathol 23: 1011-1020.

    Google Scholar 

  • Jarrett P, Thomson W, Mackie R (1999) Immunohistochemistry and sentinel node biopsy in melanoma: the use of tyrosinase and Melan A. Br J Dermatol 141: 361.

    Google Scholar 

  • Jungbluth AA, Busam KL, Gerald WL, Stockert E, Coplan KA, Iversen K, MacGregor DP, Old LJ, Chen Y-T ( 1998) An anti-melan A monoclonal antibody for the detection of malignant melanoma in paraffin embedded tissues. Am J Surg Pathol 22: 595-602.

    Google Scholar 

  • Kanitakis J, Hermier C, Cinouvet B, Thivolet J (1991) Reactivity of HMB 45 monoclonal antibody with sweat-gland tumours of the skin. Acta Derm Venereol (Stockh) 71: 426-428.

    Google Scholar 

  • Kauffmann O, Koch S, Burghardt J, Audring H, Dietel M (1998) Tyrosinase, melan A and KBA62 as markers for the immuno-histochemical identification of metastatic amelanotic melanomas on paraffin sections. Modern Pathol 11: 740-746.

    Google Scholar 

  • Mackie RM, Campbell I, Turbitt ML (1984) Use of NKIC3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol 37: 367-372.

    Google Scholar 

  • Magennis DP, Orchard GE (1999) Malignant melanoma, death by image and ignorance, diagnosis by surgical excision and laboratory investigation. Br J Biomed Sci 56: 134-144.

    Google Scholar 

  • Orchard GE, Wilson Jones E (1994) Immunocytochemistry in the diagnosis of malignant melanoma. Br J Biomed Sci 51: 44-56.

    Google Scholar 

  • Orchard G (1998) Melan A (Mart-1): a new monoclonal antibody antibody for malignant melanoma diagnosis. Br J Biomed Sci 55: 8-9.

    Google Scholar 

  • Wick MR, Swanson PE, Rocamara A (1988) Recognition of malignant melanoma by monoclonal antibody HMB 45. J Cut Pathol 15: 201-207.

    Google Scholar 

  • Wick MR, Swanson PE, Ritter JH, Fitzgibbon JF (1993) The immunohistology of cutaneous neoplasia. J Cut Pathol 20: 481-497.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Histopathology Department, St. John's Dermatology Centre, St. Thomas' Hospital, London, SE1 7EH, UK

    G.E. Orchard

Authors
  1. G.E. Orchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orchard, G. Comparison of Immunohistochemical Labelling of Melanocyte differentiation Antibodies Melan-A, Tyrosinase and HMB 45 with NKIC3 and S100 Protein in the Evaluation of Benign Naevi and Malignant Melanoma. Histochem J 32, 475–481 (2000). https://doi.org/10.1023/A:1004192232357

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1004192232357

Keywords

Search

Navigation